Actavis, Inc. (NYSE: ACT) Actavis, Inc. is a gl

Actavis, Inc. (NYSE: ACT)

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.

Actavis develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter products in more than 60 countries. Actavis Specialty Brands is Actavis' global branded specialty pharmaceutical business focused in the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands also has a portfolio of five biosimilar products in development in Women's Health and Oncology.  Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
http://www.actavis.com/en/default.htm

Activis Announcement behind the Growing Investor Interest -

Actavis ( NYSE: ACT ), announced on Monday that they entered into a definitive agreement is to acquire Warner Chilcott (NASDAQ: WCRX), in order to create a 'Global Specialty Pharmaceutical Company'.

"If successfully completed, the transaction will create a leading global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest U.S. specialty pharmaceutical company with approximately $3 billion in annual revenues focused on core therapeutic categories of Women's Health, Gastroenterology, Urology and Dermatology.  The proposed transaction has been unanimously approved by the Boards of Directors of Actavis, Inc. and Warner Chilcott plc, and is supported by the management teams of both companies."
http://ir.actavis.com/phoenix.zhtml?c=65778&a...ID=1821961